| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$21.2M | ROE | −155.66% |
| Net Margin | — | ROIC | — |
| Debt / Equity | 0.02 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $73.8M | Trading Days | 949 |
| 52W High | 4.34 |
| 52W Low | 1.41 |
| % Off High | −60.14% |
| YTD | −46.27% | 1Y | 6.79% |
| 3Y | −55.53% | 5Y | −45.08% |
| Since incept. (ann.) | −31.96% |
| Ann. Volatility (1Y) | 110.67% | Ann. Volatility (3Y) | 97.15% |
| Sharpe (1Y) | 0.64 | Sharpe (3Y) | 0.22 |
| Max Drawdown (1Y) | −61.96% | Max Drawdown (3Y) | −81.43% |
| Beta (3Y, vs SPY) | −0.36 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MAIA | MAIA Biotechnology, Inc. | $75.4M | — |
| ACET | Adicet Bio, Inc. | $76.7M | — |
| XBIT | XBiotech Inc. | $69.2M | — |
| IBIO | iBio, Inc. | $69.1M | — |
| TLPH | TALPHERA, INC. | $67.5M | — |
| LFVN | Lifevantage Corp | $81.1M | 8.6 |
| RNTX | Rein Therapeutics, Inc. | $66.9M | — |
| OSTX | OS Therapies Inc | $66.8M | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $66.3M | — |
| ACRV | Acrivon Therapeutics, Inc. | $65.9M | — |
| MNOV | MEDICINOVA INC | $65.5M | — |
| CYPHERPUNK TECHNOLOGIES INC. |
| $65.4M |
| 8.8 |
